Dual anti-HER2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC

Dual anti-HER2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC

Abstract Epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and hypoxia are associated with radioresistance. The goal of this study is to study the synergy of anti-HER2, trastuzumab, and anti-EGFR, cetuximab, and characterize the tumor microenvironment componen...

Full description

Bibliographic Details
Main Authors: Patrick N. Song, Shannon E. Lynch, Chloe T. DeMellier, Ameer Mansur, Carlos A. Gallegos, Brian D. Wright, Yolanda E. Hartman, Laura E. Minton, Suzanne E. Lapi, Jason M. Warram, Anna G. Sorace
Format: Article
Language:English
Published: Nature Portfolio 2024-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-024-52897-5

Internet

https://doi.org/10.1038/s41598-024-52897-5

Similar Items